603456 九洲药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.9548.4597.13115.02018.659
总资产报酬率 ROA (%)1.6246.7195.51511.01212.320
投入资产回报率 ROIC (%)1.8747.8726.43913.19615.313

边际利润分析
销售毛利率 (%)36.37236.85233.78337.65634.660
营业利润率 (%)18.31016.79114.18821.28720.347
息税前利润/营业总收入 (%)18.93816.39112.64920.00618.689
净利润/营业总收入 (%)14.01513.22611.76418.67316.914

收益指标分析
经营活动净收益/利润总额(%)101.517132.144127.672105.670105.420
价值变动净收益/利润总额(%)2.3020.387-1.113-1.640-3.003
营业外收支净额/利润总额(%)0.009-0.598-0.2170.413-0.371

偿债能力分析
流动比率 (X)3.8283.5102.9673.8121.804
速动比率 (X)2.7862.6132.0252.6290.891
资产负债率 (%)15.44417.09322.62621.36932.119
带息债务/全部投入资本 (%)1.4301.6466.6386.92911.708
股东权益/带息债务 (%)6,715.0575,819.3161,362.1821,301.104720.957
股东权益/负债合计 (%)543.671481.360339.070364.874208.389
利息保障倍数 (X)30.216-54.571-8.385-14.610-11.810

营运能力分析
应收账款周转天数 (天)75.64872.39675.26253.23047.541
存货周转天数 (天)169.444173.065204.811208.092187.365